BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

731 related articles for article (PubMed ID: 15254063)

  • 21. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease.
    Oudit GY; Sun H; Kerfant BG; Crackower MA; Penninger JM; Backx PH
    J Mol Cell Cardiol; 2004 Aug; 37(2):449-71. PubMed ID: 15276015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
    Panwalkar A; Verstovsek S; Giles FJ
    Cancer; 2004 Feb; 100(4):657-66. PubMed ID: 14770419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy.
    Mills GB; Lu Y; Fang X; Wang H; Eder A; Mao M; Swaby R; Cheng KW; Stokoe D; Siminovitch K; Jaffe R; Gray J
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):125-41. PubMed ID: 11706404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of PTEN and Akt in the regulation of growth and apoptosis in human osteoblastic cells.
    Nielsen-Preiss SM; Silva SR; Gillette JM
    J Cell Biochem; 2003 Dec; 90(5):964-75. PubMed ID: 14624456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1.
    Bruni P; Boccia A; Baldassarre G; Trapasso F; Santoro M; Chiappetta G; Fusco A; Viglietto G
    Oncogene; 2000 Jun; 19(28):3146-55. PubMed ID: 10918569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling.
    Paez J; Sellers WR
    Cancer Treat Res; 2003; 115():145-67. PubMed ID: 12613196
    [No Abstract]   [Full Text] [Related]  

  • 27. Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth.
    Edwards LA; Thiessen B; Dragowska WH; Daynard T; Bally MB; Dedhar S
    Oncogene; 2005 May; 24(22):3596-605. PubMed ID: 15782140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
    Pene F; Claessens YE; Muller O; ViguiƩ F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D
    Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells.
    Tanaka M; Koul D; Davies MA; Liebert M; Steck PA; Grossman HB
    Oncogene; 2000 Nov; 19(47):5406-12. PubMed ID: 11103942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN.
    Pianetti S; Arsura M; Romieu-Mourez R; Coffey RJ; Sonenshein GE
    Oncogene; 2001 Mar; 20(11):1287-99. PubMed ID: 11313873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas.
    Kurose K; Zhou XP; Araki T; Cannistra SA; Maher ER; Eng C
    Am J Pathol; 2001 Jun; 158(6):2097-106. PubMed ID: 11395387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stem cells. PTEN--coupling tumor suppression to stem cells?
    Penninger JM; Woodgett J
    Science; 2001 Dec; 294(5549):2116-8. PubMed ID: 11739945
    [No Abstract]   [Full Text] [Related]  

  • 33. Regulation of sensitivity to TRAIL by the PTEN tumor suppressor.
    Whang YE; Yuan XJ; Liu Y; Majumder S; Lewis TD
    Vitam Horm; 2004; 67():409-26. PubMed ID: 15110188
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells.
    Lin HK; Hu YC; Lee DK; Chang C
    Mol Endocrinol; 2004 Oct; 18(10):2409-23. PubMed ID: 15205473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis.
    Besson A; Robbins SM; Yong VW
    Eur J Biochem; 1999 Aug; 263(3):605-11. PubMed ID: 10469123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cowden disease and the PTEN gene: a successfully clinical and biological combined approach].
    Longy M
    Bull Cancer; 2001 Dec; 88(12):1153-8. PubMed ID: 11792608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation.
    Liu JL; Sheng X; Hortobagyi ZK; Mao Z; Gallick GE; Yung WK
    Mol Cell Biol; 2005 Jul; 25(14):6211-24. PubMed ID: 15988030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PI3K/PTEN signaling in tumorigenesis and angiogenesis.
    Jiang BH; Liu LZ
    Biochim Biophys Acta; 2008 Jan; 1784(1):150-8. PubMed ID: 17964232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo.
    Choe G; Horvath S; Cloughesy TF; Crosby K; Seligson D; Palotie A; Inge L; Smith BL; Sawyers CL; Mischel PS
    Cancer Res; 2003 Jun; 63(11):2742-6. PubMed ID: 12782577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth.
    Altomare DA; You H; Xiao GH; Ramos-Nino ME; Skele KL; De Rienzo A; Jhanwar SC; Mossman BT; Kane AB; Testa JR
    Oncogene; 2005 Sep; 24(40):6080-9. PubMed ID: 15897870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.